Since 2009, the μTASWako i30 system has been used to measure biomarkers of hepatocellular carcinoma (HCC), such as AFP, AFP-L3%, and PIVKA-II, using a fluorescence immunoassay based on the liquid-phase binding assay-electrokinetic analyte transport assay method combined with isotachophoresis (ITP) and capillary gel electrophoresis (CGE). This evidence concerns the gene AFP and hepatocellular carcinoma.